
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Experts discuss the critical importance of early identification and consistent application of appropriate treatments for fibromyalgia patients to optimize their long-term health outcomes and quality of life.
Video content above is prompted by the following: